| Year |
Citation |
Score |
| 2013 |
Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, et al. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. The Prostate. 73: 328-35. PMID 22887343 DOI: 10.1002/Pros.22573 |
0.706 |
|
| 2012 |
Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. Internal Medicine Journal. 42: 374-80. PMID 21395960 DOI: 10.1111/J.1445-5994.2011.02473.X |
0.704 |
|
| 2011 |
Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Thompson PA. Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer. American Journal of Men's Health. 5: 272-8. PMID 21613377 DOI: 10.1177/1557988310390030 |
0.708 |
|
| 2010 |
Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 1035-43. PMID 20647337 DOI: 10.1158/1940-6207.Capr-09-0143 |
0.707 |
|
| 2010 |
Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. The Prostate. 70: 883-8. PMID 20135645 DOI: 10.1002/Pros.21122 |
0.701 |
|
| 2009 |
Frank DH, Kimler BF, Fabian CJ, Ranger-Moore J, Yozwiak M, Bartels HG, Alberts DS, Bartels PH. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months. Breast Cancer Research and Treatment. 115: 661-8. PMID 19125322 DOI: 10.1007/S10549-008-0274-0 |
0.325 |
|
| 2008 |
Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, Alberts DS. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutrition and Cancer. 60: 325-30. PMID 18444166 DOI: 10.1080/01635580701840391 |
0.304 |
|
| 2006 |
Clouser MC, Harris RB, Roe DJ, Saboda K, Ranger-Moore J, Duckett L, Alberts DS. Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 2292-7. PMID 17119060 DOI: 10.1158/1055-9965.Epi-06-0405 |
0.306 |
|
| 2005 |
Derby MP, McNally J, Ranger-Moore J, Hulette L, Villar R, Hysong T, MacNeill E, Lebowitz M, Burgess J. Poison Control Center--based syndromic surveillance for foodborne illness. Mmwr. Morbidity and Mortality Weekly Report. 54: 35-40. PMID 16177691 |
0.505 |
|
| 2005 |
Ranger-Moore J, Alberts DS, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, Bartels PH. Karyometry in the early detection and chemoprevention of intraepithelial lesions. European Journal of Cancer (Oxford, England : 1990). 41: 1875-88. PMID 16087328 DOI: 10.1016/J.Ejca.2005.07.002 |
0.352 |
|
| 2003 |
Montironi R, Scarpelli M, Mazzucchelli R, Hamilton PW, Thompson D, Ranger-Moore J, Bostwick DG, Bartels PH. Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma. Human Pathology. 34: 893-901. PMID 14562285 DOI: 10.1016/S0046-8177(03)00341-1 |
0.314 |
|
| Show low-probability matches. |